-transparent.png){kind=logo}
CGS 26303 is a potent and structurally unique non-peptidic inhibitor of neutral endopeptidase (NEP) capable of protecting atrial natriuretic peptide (ANP) from enzymatic degradation. In addition, CGS 26303 displays modest endothelin-converting enzyme (ECE) inhibitory activity in vitro. Unlike CGS 24592, a potent but selective NEP inhibitor, CGS 26303 significantly blocks endothelin-1 production in rats after exogenous administration of big ET-1 and reduces the mean arterial pressure in spontaneously hypertensive rats during chronic administration. These results suggest that CGS 26303 represents a new class of therapeutic agents with potential benefits for the treatment of cardiovascular and renal disorders.
S De Lombaert, and
R D Ghai, and
A Y Jeng, and
A J Trapani, and
R L Webb
January 2000,
Life sciences,
S De Lombaert, and
R D Ghai, and
A Y Jeng, and
A J Trapani, and
R L Webb
August 2002,
Clinical science (London, England : 1979),
S De Lombaert, and
R D Ghai, and
A Y Jeng, and
A J Trapani, and
R L Webb
January 1998,
Journal of cardiovascular pharmacology,
S De Lombaert, and
R D Ghai, and
A Y Jeng, and
A J Trapani, and
R L Webb
January 1995,
Journal of cardiovascular pharmacology,
S De Lombaert, and
R D Ghai, and
A Y Jeng, and
A J Trapani, and
R L Webb
November 1993,
Journal of medicinal chemistry,
S De Lombaert, and
R D Ghai, and
A Y Jeng, and
A J Trapani, and
R L Webb
January 2005,
Cardiovascular drug reviews,
S De Lombaert, and
R D Ghai, and
A Y Jeng, and
A J Trapani, and
R L Webb
October 2012,
Life sciences,
S De Lombaert, and
R D Ghai, and
A Y Jeng, and
A J Trapani, and
R L Webb
February 1995,
Biochemical and biophysical research communications,
S De Lombaert, and
R D Ghai, and
A Y Jeng, and
A J Trapani, and
R L Webb
August 2002,
Clinical science (London, England : 1979),
S De Lombaert, and
R D Ghai, and
A Y Jeng, and
A J Trapani, and
R L Webb
January 1994,
The Journal of pharmacology and experimental therapeutics,
